Fixed-ratio combination of basal insulin and GLP-1 receptor agonist: is two better than one?

被引：1
|
作者：
Del Prato, Stefano [1 ]
机构：
[1] Univ Pisa, Dept Clin & Expt Med, Sect Diabet & Metab Dis, I-56124 Pisa, Italy
来源：
LANCET DIABETES & ENDOCRINOLOGY | 2014年 / 2卷 / 11期
关键词：
D O I：
10.1016/S2213-8587(14)70185-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：856 / 858
页数：4
相关论文
共 50 条
  • [1] A review of the new GLP-1 receptor agonist/basal insulin fixed-ratio combination products
    Nuffer, Wesley
    Guesnier, Ashley
    Trujillo, Jennifer M.
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2018, 9 (03) : 69 - 79
  • [2] Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes
    Ostergaard, Lauge
    Frandsen, Christian Seerup
    Dejgaard, Thomas Fremming
    Madsbad, Sten
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (06) : 621 - 632
  • [3] Free Versus Fixed-Ratio Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect Treatment Comparison
    Jung, Han Na
    Cho, Yun Kyung
    Min, Se Hee
    Kim, Hwi Seung
    Kim, Ye-Jee
    Park, Joong-Yeol
    Lee, Woo Je
    Jung, Chang Hee
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [4] Successful Resolution of Glucose Toxicity With the Use of Fixed-Ratio Combination Injection of Basal Insulin and Short-Acting Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist
    Miura, Hiroshi
    Muramae, Naokazu
    Mori, Kenta
    Otsui, Kazunori
    Sakaguchi, Kazuhiko
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (06)
  • [5] EARLY INTENSIFICATION WITH FIXED-RATIO COMBINATION OF BASAL INSULIN AND GLP-1 RECEPTOR AGONIST IN T2DM: IMPACT OF ONLINE EDUCATION ON PRIMARY CARE PHYSICIAN KNOWLEDGE AND COMPETENCE
    Trier, J.
    Griffith, G.
    Ampudia-Blasco Javier, F.
    McCarthy, R.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2019, 21 : A129 - A129
  • [6] Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?
    Rodrigo Oliveira Moreira
    Roberta Cobas
    Raquel C. Lopes Assis Coelho
    Diabetology & Metabolic Syndrome, 10
  • [7] Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?
    Moreira, Rodrigo Oliveira
    Cobas, Roberta
    Lopes Assis Coelho, Raquel C.
    DIABETOLOGY & METABOLIC SYNDROME, 2018, 10
  • [8] The role of basal insulin and GLP-1 receptor agonist combination products in the management of type 2 diabetes
    Inman, Taylor R.
    Plyushko, Erika
    Austin, Nicholas P.
    Johnson, Jeremy L.
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2018, 9 (05) : 151 - 155
  • [9] Expert Opinion on Optimising Type 2 Diabetes Treatment Using Fixed-Ratio Combination of Basal Insulin and GLP-1 RA for Treatment Intensification and Simplification
    Haluzik, Martin
    Taybani, Zoltan
    Araszkiewicz, Aleksandra
    Cerghizan, Anca
    Mankovsky, Boris
    Zuhdi, Agbaria
    Malecki, Maciej
    DIABETES THERAPY, 2024, 15 (08) : 1673 - 1685
  • [10] Least Glucose Variability and Hypoglycemia Is Observed with the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION Study)
    Bajaj, Harpreet S.
    Venn, Karri
    Ye, Chenglin
    Khandwala, Hasnain
    Aslam, Nadeem
    Twum-Barima, David Y.
    Patrick, Avril
    Aronson, Ronnie
    DIABETES, 2015, 64 : A44 - A44
12345